Quelle: - pixabay.com:
Aufrufe: 48
ADOCIA Announces its Financial Calendar for 2026
| February 24, 2026 | Publication of revenue for Q4 2025 | |
| April 21, 2026 | Publication of 2025 financial statements | |
| May 12, 2026 | Publication of revenue for Q1 2026 | |
| June 3, 2026 | Annual shareholders’ meeting | |
| July 23, 2026 | Publication of revenue for Q2 2026 | |
| September 24, 2026 | Publication of mid-year financial statements as of June 30, 2026 | |
| October 29, 2026 | Publication of revenue for Q3 2026 |
In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).
All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section “Regulated Information”.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLongTM, a long-acting peptide platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218443649/en/
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.